CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology® (CST) where we discuss what to expect from your time at the bench, share tips, tricks, and information.

All Posts

Webinar | Proteomics profiling of post-translational modifications in early drug discovery

Advances in mass spectrometry instrumentation and sample handling methods have propelled proteomics and extended its utility for both basic biology and early drug development. Changes in protein abundance and post-translational modification state often reflect the activity of a novel therapeutic agent as well as the sensitivity/resistance of a biological system to treatment.

Screen Shot 2018-03-27 at 3.15.03 PM

For post-translational modifications, methods to enrich modified peptides from complex mixtures have played an important role. Chief among these is immunoaffinity enrichment, where antibodies directed against post-translational modifications (or remnants thereof) are used to capture analytes of interest for mass spectrometry analysis. To expand upon these methods, here we report on an automated PTMScan® immunoaffinity enrichment protocol, developed using the Phynexus MEA benchtop robot, for concurrent processing of up to twelve samples. System optimization has included interrogating the effects of peptide incubation, washing, and antibody-resin crosslinking on the sensitivity and specificity of this automated method. Using this technology in conjunction with Ubiquitin Remnant Motif (K-ε-GG), it is now possible to identify and quantify many >10,000 distinct ubiquitination events from cultured cells and tissue samples. This webinar will focus on the utility of the PTMScan method in early drug discovery and the future of automation in multiplexed analysis of cellular signaling.

During this webinar, viewers will learn about:

  • How changes in post-translational modification can be used to assess activation states of novel therapeutic targets;
  • Benchtop robot automation of the PTMScan® immunoaffinity enrichment protocol, enabling concurrent processing of 12 samples;
  • Utility of the PTMScan® method for early drug discovery, and the future of automation in multiplexed analysis of cellular signaling.

Sign up for webinar

PTMScan® is a registered trademark of Cell Signaling Technology, Inc.

Chris S
Chris S
Chris Sumner is the Editor-in-Chief of Lab Expectations. When he's not reading/writing about curing disease, he's hiking in the woods, playing guitar, or searching for the world's best lobster roll.

Related Posts

Therapeutic Approaches for the Treatment of Multiple Myeloma

What Is Multiple Myeloma? Multiple myeloma is a cancer of plasma cells that is treatable, but not curable...
Andrea T Jul 2, 2022 5:16:45 PM

Hypoxia and Its Role in Metabolism

Hypoxia, defined as the deficiency of oxygen in the biotic environment, causes cellular stress and alters...
Chris S Jun 8, 2022 3:00:00 AM

It's All about the Affinity

In 2012 Roux et al. published in the Journal of Cell Biology a pioneering approach to identify the intera...
Charles F May 25, 2022 3:00:00 AM